Revenue + Forward P/E
United Therapeutics Corporation (UTHR) quarterly revenue and forward P/EForward P/E: 19.4x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$21.45B
Enterprise value
$21.36B
P/E ratio (TTM)
18.06x
P/S ratio (TTM)
7.08x
P/B ratio
3.90x
EV/Sales
6.74x
EV/EBITDA
12.46x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$3.18B
Gross profit (TTM)
$2.80B
Operating income (TTM)
$1.52B
EBITDA (TTM)
$1.82B
Net income (TTM)
$1.33B
Free cash flow (TTM)
$1.04B
Margins & returns
Gross margin
86.58%
Operating margin
45.34%
Profit margin
40.61%
Return on equity
19.24%
Return on assets
19.17%
Per-share metrics
EPS (TTM)
$29.60
Dividend yield
0.00%
Beta
0.58
Capital structure
Cash & equivalents
$1.56B
Total debt
$37.60M
Net debt
$-1.52B
Shares outstanding
42.45M
Financial health
Current ratio
6.60
Debt / equity
0.01
Debt / assets
0.00
Interest coverage
77.81
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.14T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.80B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.20B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.07B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.41B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $21.45B | 18.06x | 7.08x | 12.46x | - |